Trial Profile
Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Furmonertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Allist Pharmaceuticals
- 31 Jan 2021 Results of sub-group analysis assessing CNS efficacy of different AST2818 doses, presented at the 2020 World Conference on Lung Cancer.
- 30 Jan 2020 Results (n=130) from NCT02973763 (n=14) and NCT03127449(n=116), assessing clinically efficacy with an acceptable toxicity profile in advanced NSCLC patients (including those with CNS metastases) with EGFR T790M mutation, published in the Journal of Thoracic Oncology
- 02 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.